دورية أكاديمية
Six-Year Outcomes in Subjects with Polypoidal Choroidal Vasculopathy in the EVEREST II Study.
| العنوان: | Six-Year Outcomes in Subjects with Polypoidal Choroidal Vasculopathy in the EVEREST II Study. |
|---|---|
| المؤلفون: | Teo KYC; Singapore Eye Research Institute, Singapore National Eye Centre, 11 Third Hospital Avenue, Singapore, 168751, Singapore., Park KH; Department of Ophthalmology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea., Ngah NF; Hospital Selayang, Batu Caves, Selangor, Malaysia., Chen SJ; Department of Ophthalmology, Taipei Veterans General Hospital, School of Medicine, National Yang Ming Chiao Yung University, 201 Shih-Pai Road, Taipei, 112, Taiwan., Ruamviboonsuk P; Department of Ophthalmology, College of Medicine, Rangsit University, Rajavithi Hospital, Bangkok, Thailand., Mori R; Department of Ophthalmology, Nihon University School of Medicine, Tokyo, Japan., Kondo N; Miyake Eye Hospital Ophthalmology, Ozone, Kita-ku, Nagoya City, Japan., Lee WK; Nune Eye Hospital, Seoul, South Korea., Rajagopalan R; Tan Tock Seng Hospital, National Healthcare Group Eye Institute, Singapore, Singapore., Obata R; The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan., Wong IYH; Hong Kong Sanatorium and Hospital, Happy Valley, Hong Kong., Chee C; National University Hospital, Singapore, Singapore., Terasaki H; Nagoya University Hospital, Nagoya City, Aichi, Japan., Sekiryu T; Fukushima Medical University Hospital, Fukushima City, Fukushima, Japan., Chen SC; Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan., Yanagi Y; Singapore Eye Research Institute, Singapore National Eye Centre, 11 Third Hospital Avenue, Singapore, 168751, Singapore.; Duke-NUS Medical School, National University of Singapore, Singapore, Singapore., Honda S; Osaka Metropolitan University Hospital, Osaka City, Osaka, Japan., Lai TYY; Department of Ophthalmology and Visual Sciences, Hong Kong Eye Hospital, 147K Argyle Street, Kowloon, Hong Kong., Cheung CMG; Singapore Eye Research Institute, Singapore National Eye Centre, 11 Third Hospital Avenue, Singapore, 168751, Singapore. gemmy.cheung.c.m@singhealth.com.sg.; Department of Ophthalmology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea. gemmy.cheung.c.m@singhealth.com.sg. |
| المصدر: | Ophthalmology and therapy [Ophthalmol Ther] 2024 Apr; Vol. 13 (4), pp. 935-954. Date of Electronic Publication: 2024 Feb 03. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer Healthcare Country of Publication: England NLM ID: 101634502 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2193-8245 (Print) NLM ISO Abbreviation: Ophthalmol Ther Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [London] : Springer Healthcare |
| مستخلص: | Introduction: The EVEREST II study previously reported that intravitreally administered ranibizumab (IVR) combined with photodynamic therapy (PDT) achieved superior visual gain and polypoidal lesion closure compared to IVR alone in patients with polypoidal choroidal vasculopathy (PCV). This follow-up study reports the long-term outcomes 6 years after initiation of the EVEREST II study. Methods: This is a non-interventional cohort study of 90 patients with PCV from 16 international trial sites who originally completed the EVEREST II study. The long-term outcomes were assessed during a recall visit at about 6 years from commencement of EVEREST II. Results: The monotherapy and combination groups contained 41 and 49 participants, respectively. The change in best-corrected visual acuity (BCVA) from baseline to year 6 was not different between the monotherapy and combination groups; - 7.4 ± 23.0 versus - 6.1 ± 22.4 letters, respectively. The combination group had greater central subfield thickness (CST) reduction compared to the monotherapy group at year 6 (- 179.9 vs - 74.2 µm, p = 0.011). Fewer eyes had subretinal fluid (SRF)/intraretinal fluid (IRF) in the combination versus monotherapy group at year 6 (35.4% vs 57.5%, p = 0.032). Factors associated with BCVA at year 6 include BCVA (year 2), CST (year 2), presence of SRF/IRF at year 2, and number of anti-VEGF treatments (years 2-6). Factors associated with presence of SRF/IRF at year 6 include combination arm (OR 0.45, p = 0.033), BCVA (year 2) (OR 1.53, p = 0.046), and presence of SRF/IRF (year 2) (OR 2.59, p = 0.042). Conclusion: At 6 years following the EVEREST II study, one-third of participants still maintained good vision. As most participants continued to require treatment after exiting the initial trial, ongoing monitoring and re-treatment regardless of polypoidal lesion status are necessary in PCV. Trial Registration: ClinicalTrials.gov identifier, NCT01846273. (© 2024. The Author(s).) |
| References: | N Engl J Med. 2006 Oct 5;355(14):1419-31. (PMID: 17021318) JAMA Ophthalmol. 2018 Jul 1;136(7):786-793. (PMID: 29801063) Ophthalmology. 2021 Mar;128(3):443-452. (PMID: 32795496) JAMA Ophthalmol. 2017 Nov 1;135(11):1206-1213. (PMID: 28983556) Ophthalmology. 2015 Jun;122(6):1212-9. (PMID: 25846847) JAMA Ophthalmol. 2020 Sep 1;138(9):935-942. (PMID: 32672800) Asia Pac J Ophthalmol (Phila). 2020 May-Jun;9(3):260-268. (PMID: 32332215) Sci Rep. 2021 Nov 3;11(1):21572. (PMID: 34732787) Retina. 2015 Aug;35(8):1577-93. (PMID: 25719986) Am J Ophthalmol. 2013 Mar;155(3):438-447.e1. (PMID: 23218705) Acta Ophthalmol. 2021 Aug;99(5):e706-e714. (PMID: 33289345) Ophthalmol Retina. 2019 Mar;3(3):220-229. (PMID: 31014698) Ophthalmology. 2012 Jun;119(6):1175-83. (PMID: 22306121) Am J Ophthalmol. 2019 Aug;204:80-89. (PMID: 30849345) Asia Pac J Ophthalmol (Phila). 2023 Mar-Apr 01;12(2):184-195. (PMID: 36728294) Ophthalmology. 2013 Nov;120(11):2292-9. (PMID: 23642856) Ophthalmology. 2018 May;125(5):708-724. (PMID: 29331556) N Engl J Med. 2006 Oct 5;355(14):1432-44. (PMID: 17021319) Eye (Lond). 2022 Feb;36(2):257-265. (PMID: 34262165) |
| معلومات مُعتمدة: | NMRC/LCG/004/2018 National Medical Research Council Singapore Open Fund Large Collaborative Grant |
| فهرسة مساهمة: | Keywords: Anti-vascular endothelial growth factor (VEGF) therapies; BCVA; EVEREST II; Long-term outcomes; Polypoidal choroidal vasculopathy |
| سلسلة جزيئية: | ClinicalTrials.gov NCT01846273 |
| تواريخ الأحداث: | Date Created: 20240203 Latest Revision: 20240307 |
| رمز التحديث: | 20240307 |
| مُعرف محوري في PubMed: | PMC10912383 |
| DOI: | 10.1007/s40123-024-00888-0 |
| PMID: | 38308746 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 2193-8245 |
|---|---|
| DOI: | 10.1007/s40123-024-00888-0 |